Free Access
Issue
Med Sci (Paris)
Volume 31, Number 2, Février 2015
Page(s) 132 - 134
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153102006
Published online 04 March 2015
  1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropath 1991 ; 82 : 239–259. [CrossRef] [PubMed] [Google Scholar]
  2. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998 ; 393 : 702–705. [CrossRef] [PubMed] [Google Scholar]
  3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992 ; 42 : 631–639. [CrossRef] [PubMed] [Google Scholar]
  4. Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012 ; 73 : 1216–1227. [CrossRef] [PubMed] [Google Scholar]
  5. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010 ; 11 : 55–59. [Google Scholar]
  6. Augustinack JC, Schneider A, Mandelkow E-M, Hymen BT. Specific Tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 2002 ; 103 : 26–35. [CrossRef] [PubMed] [Google Scholar]
  7. Deters N, Ittner LM, Gotz J. Divergent phosphorylation pattern of Tau in P301L tau transgenic mice. Eur J Neurosci 2008 ; 28 : 137–147. [CrossRef] [PubMed] [Google Scholar]
  8. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 2009 ; 8 : 783–793. [CrossRef] [PubMed] [Google Scholar]
  9. Pooler AM, Phillips EC, Lau DH, et al. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013 ; 14 : 389–394. [CrossRef] [PubMed] [Google Scholar]
  10. Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. CSH Perspect Med 2011 ; 1 : a006437. [Google Scholar]
  11. Noack M, Leyk J, Richter-Landsberg C. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. Glia 2014 ; 62 : 535–547. [CrossRef] [PubMed] [Google Scholar]
  12. Wang YP, Biernat J, Pickhardt M, et al. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci USA 2007 ; 104 : 10252–10257. [CrossRef] [Google Scholar]
  13. Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 2013 ; 56 : 4135–4155. [CrossRef] [PubMed] [Google Scholar]
  14. Yanamandra K, Kfoury N, Mahan TE, et al. Anti-Tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013 ; 80 : 402–414. [CrossRef] [PubMed] [Google Scholar]
  15. Asuni AA, Boutajangout A, Quatermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007 ; 27 : 9115–9129. [CrossRef] [PubMed] [Google Scholar]
  16. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011 ; 118 : 658–667. [CrossRef] [PubMed] [Google Scholar]
  17. Troquier L, Cailleriez R, Burnouf S, et al. Targeting phosphor-Ser422 by active Tau immunotherapy in the THYTau22 mouse model : a suitable therapeutic approach. Curr Alzheimer Res 2012 ; 9 : 397–405. [CrossRef] [PubMed] [Google Scholar]
  18. Rozenstein-Tsalovich L, Grigoriadis N, Lourbopoulos A, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013 ; 248 : 451–456. [CrossRef] [PubMed] [Google Scholar]
  19. Grueninger F, Bohrmann B, Czech C, et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 2010 ; 37 : 294–306. [CrossRef] [PubMed] [Google Scholar]
  20. Collin L, Bohrmann B, Göpfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain 2014 ; 137 : 2834–2846. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.